Vantage Investment Advisors’s Kiora Pharmaceuticals KPRX Stock Holding History

Vantage Investment Advisors’s Portfolio KPRX Stock Details KPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$2K	Hold	1	–	–	﹤0.01%	705
2018 Q2	$3K	Hold	1	–	–	﹤0.01%	680
2018 Q1	$2K	Hold	1	–	–	﹤0.01%	737
2017 Q4	$7K	Hold	1	–	–	﹤0.01%	635
2017 Q3	$8K	Hold	1	–	–	﹤0.01%	598
2017 Q2	$9K	Hold	1	–	–	﹤0.01%	570
2017 Q1	$17K	Hold	1	–	–	0.01%	429
2016 Q4	$11K	Hold	1	–	–	﹤0.01%	491
2016 Q3	$11K	Hold	1	–	–	﹤0.01%	476
2016 Q2	$17K	Hold	1	–	–	0.01%	442
2016 Q1	$20K	Hold	1	–	–	0.01%	408
2015 Q4	$18K	Hold	1	–	–	0.01%	405
2015 Q3	$19K	Buy	+1	New	+$22.9K	0.01%	379

Other funds holding KPRX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vantage Investment Advisors's KPRX Position: Q3 2018 in Review

Vantage Investment Advisors held its Kiora Pharmaceuticals (KPRX) position steady in Q3 2018 at 1 share worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #705.

Vantage Investment Advisors first reported a position in KPRX in Q3 2015 and has held it in 13 quarters since. The position peaked at $20K in Q1 2016. 20 funds tracked by Wall St. Rank hold KPRX as of Q3 2018.

Vantage Investment Advisors held 1 share of Kiora Pharmaceuticals worth $2K as of Q3 2018.
Vantage Investment Advisors left its Kiora Pharmaceuticals share count unchanged in Q3 2018.
Kiora Pharmaceuticals made up ﹤0.01% of Vantage Investment Advisors's portfolio in Q3 2018, its #705 holding.
Vantage Investment Advisors first reported a position in Kiora Pharmaceuticals in Q3 2015 and has held it in 13 quarters since.
Vantage Investment Advisors's Kiora Pharmaceuticals position peaked at $20K in Q1 2016.
20 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q3 2018.

Based on Vantage Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.